Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Using sole-supply providers, New Zealand generic drug prices were considerably cheaper than corresponding drugs in Australia, Britain and Canada, according to the Pharmaceutical Management Agency's annual review for 2009
You may also be interested in...
New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix
TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market
New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix
TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market
New Zealand's PHARMAC Widens Access To Atorvastatin By Awarding Sole Supply Status For Generic
PERTH, Australia - Mylan's Lorstat (atorvastatin) will become New Zealand's only subsidized atorvastatin generic beginning Dec. 1. In addition, the Special Authority, which requires doctors to call in to receive authority to prescribe the drug, will be removed, reducing paperwork for prescribers and widening access to the drug